{
    "clinical_study": {
        "@rank": "100986", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo plus standard treatment. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain."
            }, 
            {
                "arm_group_label": "Triptolide-Containing Formulation", 
                "arm_group_type": "Experimental", 
                "description": "Triptolide-Containing Formulation (1mg/kg/d) was prescribed; Dosage will be adjusted if necessary according to the adverse events monitoring."
            }
        ], 
        "brief_summary": {
            "textblock": "Triptolide was shown in experimental studies to inhibit the cyst formation and growth in\n      ADPKD models, while triptolide-containing formulation was revealed to potentially slow the\n      disease progression in several proteinuric ADPKD patients in our clinical practice. It\n      remains to be shown the effect of triptolide-containing formulation on total kidney volume\n      (TKV) enlargement and renal function protection in ADPKD patients."
        }, 
        "brief_title": "Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)", 
        "completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Autosomal Dominant Polycystic Kidney Disease (ADPKD)", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Polycystic Kidney Diseases", 
                "Polycystic Kidney, Autosomal Dominant"
            ]
        }, 
        "detailed_description": {
            "textblock": "Randomized Controlled Trial"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ADPKD patient older then 40 years of age without gender limitation\n\n          -  Estimated glomerular filtration rate (eGFR) higher than 60 ml/min 1.73m2\n\n          -  documented kidney volume progression with yearly increasing rate more than 6%\n\n          -  informed consent\n\n        Exclusion Criteria:\n\n          -  Female who is planning to become pregnant, who is pregnant and/or lactating, who is\n             unwilling to use effective means of contraception\n\n          -  impaired liver function as increased liver enzymes (2-fold above normal values)\n\n          -  uncontrolled hypercholesterolemia (fasting cholesterol > 8 mmol/l) or\n             hypertriglyceridaemia (> 5 mmol/l) under lipid lowering therapy\n\n          -  granulocytopenia (white blood cell < 3,000/mm3) or thrombocytopenia (platelets <\n             100,000/mm3)\n\n          -  hepatitis B or C, HIV infection\n\n          -  malignancy\n\n          -  mental illness that interfere with the patient ability to comply with the protocol\n\n          -  drug or alcohol abuse\n\n          -  known hypersensitivity to similar drugs as Triptolide-Containing Formulation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115659", 
            "org_study_id": "CZKIPLA-ADPKD-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Triptolide-Containing Formulation", 
                "description": "Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.", 
                "intervention_name": "Triptolide-Containing Formulation", 
                "intervention_type": "Drug", 
                "other_name": "Triptolide-Containing Formulation plus standard treatment."
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo plus standard treatment."
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Triptolide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "ADPKD", 
            "triptolide"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "contact": {
                "email": "chlmei1954@126.com", 
                "last_name": "Changlin Mei, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200003"
                }, 
                "name": "Shanghai Changzheng Hospital"
            }, 
            "investigator": {
                "last_name": "Changlin Mei, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Controlled Trial of Triptolide-Containing Formulation for Autosomal Dominant Polycystic Kidney Disease (ADPKD)", 
        "overall_contact": {
            "email": "chlmei1954@126.com", 
            "last_name": "Changlin Mei, MD"
        }, 
        "overall_official": {
            "affiliation": "Shanghai Changzheng Hospital", 
            "last_name": "Changlin Mei, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Science and Technology Commission of Shanghai Municipality", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "renal volume measured by high resolution magnetic resolution imaging", 
            "safety_issue": "No", 
            "time_frame": "2 yrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115659"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shanghai Changzheng Hospital", 
            "investigator_full_name": "Mei changlin", 
            "investigator_title": "Professor,Director of the Kidney Institute", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Estimated glomerular filtration rate (eGFR)", 
                "safety_issue": "Yes", 
                "time_frame": "2 yrs"
            }, 
            {
                "measure": "Adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "2 yrs"
            }
        ], 
        "source": "Shanghai Changzheng Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Changzheng Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}